Treatment-by-center interaction was also GSK2245840 nmr investigated. Within-treatment comparisons were analyzed using one-sample t-tests. All treatment comparisons were made at a two-sided significance level of 0.05. The proportion of patients in each treatment group achieving a successful reduction in diastolic BP was compared using a logistic regression model with treatment and center as co-factors and the dichotomous response as the dependent variable. Table I Baseline demographic characteristics at the end of monotherapy Results Continued

monotherapy with benazepril 40 mg/day after randomization to double-blind therapy reduced MSDBP from baseline by 7.1 mmHg in White patients (p < 0.0001) and by 4.77 mmHg in Black patients (p < 0.0002), and reduced MSSBP by 6.00 mmHg in White patients (p < 0.0001) and by 1.85 mmHg in Black patients (p-value not significant). The difference in MSDBP Selleckchem CHIR98014 was not significant between Black and White patients, but the difference in MSSBP was significant (p < 0.05). Continued monotherapy with amlodipine 10 mg/day AZD2171 manufacturer decreased MSDBP from baseline by 9.2 mmHg in White patients and by 8.9 mmHg in Black patients (p < 0.001), and reduced MSSBP by 5.8 mmHg in White patients and by 9.4 mmHg in Black patients (p

< 0.001 for both). There was no difference in the reductions of MSDBP and MSSBP between the two groups. The combination treatment of amlodipine/benazepril 10/20 mg/day decreased MSDBP from baseline by 12.99 mmHg in White patients

(p < 0.0001) and by 8.80 mmHg in Black patients (p < 0.0001), and decreased MSSBP by 13.72 mmHg in White patients (p < 0.0001) and by 8.72 mmHg in Black patients (p < 0.0001). This drug combination resulted in significantly greater BP reductions in White patients than in Black patients (p < 0.004). The high-dose amlodipine/benazepril 10/40 mg/day combination resulted in reductions from baseline of MSSBP and MSDBP by 14.33 and 13.60 mmHg, respectively, in White patients DOCK10 (p < 0.0001) and by 14.89 and 12.79 mmHg, respectively, in Black patients (p < 0.0001). In contrast with the low-dose amlodipine/benazepril combination, there was no significant difference between the groups receiving the high-dose combination (p < 0.674). The effects of combination therapy on BP are depicted in figure 2. The percentages of patients who achieved BP control (BP <140/90 mmHg) and the percentages of responders to treatment (MSDBP <90 mmHg or ≥10 mmHg decrease from baseline) are listed in table II. In the high-dose combination treatment group, the control rate was identical in Black and White patients (60.7%), whereas in the low-dose combination treatment group, the control rate was higher in White patients than in Black patients (61.2% vs 39.4%; p < 0.0023). With respect to the responder rate, there was no difference between Black and White patients for the high-dose combination (74.8% vs 77%; p < 0.639).